Cargando…

The Impact of Sarcopenia in Patients with Peritoneal Surface Disease

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Juris, Aubrey, Taylor-Gehman, Amanda, Spencer, Brianna, Schaefer, Eric, Pameijer, Colette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435582/
https://www.ncbi.nlm.nih.gov/pubmed/34526857
http://dx.doi.org/10.3389/pore.2021.638857
_version_ 1783751823524364288
author Juris, Aubrey
Taylor-Gehman, Amanda
Spencer, Brianna
Schaefer, Eric
Pameijer, Colette
author_facet Juris, Aubrey
Taylor-Gehman, Amanda
Spencer, Brianna
Schaefer, Eric
Pameijer, Colette
author_sort Juris, Aubrey
collection PubMed
description Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient’s wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery.
format Online
Article
Text
id pubmed-8435582
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84355822021-09-14 The Impact of Sarcopenia in Patients with Peritoneal Surface Disease Juris, Aubrey Taylor-Gehman, Amanda Spencer, Brianna Schaefer, Eric Pameijer, Colette Pathol Oncol Res Society Journal Archive Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient’s wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery. Frontiers Media S.A. 2021-08-30 /pmc/articles/PMC8435582/ /pubmed/34526857 http://dx.doi.org/10.3389/pore.2021.638857 Text en Copyright © 2021 Juris, Taylor-Gehman, Spencer, Schaefer and Pameijer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Society Journal Archive
Juris, Aubrey
Taylor-Gehman, Amanda
Spencer, Brianna
Schaefer, Eric
Pameijer, Colette
The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
title The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
title_full The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
title_fullStr The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
title_full_unstemmed The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
title_short The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
title_sort impact of sarcopenia in patients with peritoneal surface disease
topic Society Journal Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435582/
https://www.ncbi.nlm.nih.gov/pubmed/34526857
http://dx.doi.org/10.3389/pore.2021.638857
work_keys_str_mv AT jurisaubrey theimpactofsarcopeniainpatientswithperitonealsurfacedisease
AT taylorgehmanamanda theimpactofsarcopeniainpatientswithperitonealsurfacedisease
AT spencerbrianna theimpactofsarcopeniainpatientswithperitonealsurfacedisease
AT schaefereric theimpactofsarcopeniainpatientswithperitonealsurfacedisease
AT pameijercolette theimpactofsarcopeniainpatientswithperitonealsurfacedisease
AT jurisaubrey impactofsarcopeniainpatientswithperitonealsurfacedisease
AT taylorgehmanamanda impactofsarcopeniainpatientswithperitonealsurfacedisease
AT spencerbrianna impactofsarcopeniainpatientswithperitonealsurfacedisease
AT schaefereric impactofsarcopeniainpatientswithperitonealsurfacedisease
AT pameijercolette impactofsarcopeniainpatientswithperitonealsurfacedisease